LOXO-305 Comes Out Swinging In Battle Of BTK Inhibitors
Lilly's Loxo Presents Positive Phase I/II Data In MCL At ASH
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.
You may also be interested in...
Most of Lilly’s 2021 gains will come from its newer products, but sales of COVID-19 treatments added $500m to the company’s 2020 revenue guidance and may total $1bn-$2bn next year.
Approved in the US in May, the drug is the latest targeted therapy to emerge from Lilly’s oncology division Loxo.
As the first company with two approved chimeric antigen receptor T-cell therapies, Gilead’s Kite subsidiary has set a precedent by keeping the pricing the same as its first approved CAR-T, Yescarta.